PIL seeks curbs on antibiotics sale without prescription
A Mumbai-based lawyer has filed a public interest litigation (PIL) before the Bombay High Court seeking a directive to restrict over-the-counter sale of antibiotics in India, the world’s “largest consumer of antibiotics”.
The petition followed investigation by an activist who found that antibiotics under ‘restricted use’ were freely available over the counter across pharmacies in India.
The PIL pointed to the United Nations high-level meeting on antimicrobial resistance and said a UN declaration had asked countries to come up with an action plan to curb the misuse of antibiotics by 2018. “That the pressure is on India, the world’s largest consumer of antibiotics and where carelessness in antibiotic use and environmental antibiotic pollution has been documented,” the petition said.
Antibiotic drugs are part of a nearly Rs. 17,000-crore business in India, growing at 5-6% annually. India is one of the biggest consumers of antibiotics. These drugs are also used rampantly in agriculture, specifically for poultry and livestock.
Looking for chemical products? Let suppliers reach out to you!
2026-07-09
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
4 Pharma Firms Lose Licenses in Jammu and Kashmir Amid Illegal Drug Sales Crackdown
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
U.S. Health Chief Says No Evidence Linking Tylenol to Autism
-
Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
Recommend Reading
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Market Performance Balanced, PC Holds Steady Before the Festival
-
From Painting Walls to Total Collapse: The RMB 152 Million Debt That Tore Off the Last Veil of Asia Chuangneng’s Paint Empire
-
January China Anhydrous Hydrofluoric Acid Market Prices Shift Upward
-
Multiple-Factor Resonance Causes Lithium Carbonate to Fall from High Levels
-
Multiple Negative Factors Weigh on Butadiene Market, Leading to a Slight Decline